A Study to Evaluate the Efficacy and Safety of MCT-SR in Patients With Gastritis
NCT ID: NCT04189705
Last Updated: 2021-03-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
392 participants
INTERVENTIONAL
2019-12-30
2020-04-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Post-Marketing Surveillance of Safety and Effectiveness of Mucosta®SR Tab.
NCT05048069
A Study to Evaluate the Efficacy and Safety of AD-203
NCT04066530
A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of PMK-S005 After Oral Administration in Healthy Male Volunteers
NCT01762397
Mucosta in Gastric Ulcer Treatment, Effectiveness and Safety Evaluation
NCT01150162
Efficacy and Safety of Eupasidin-s Tab.(EUPASIDIN-S) in Gastritis Patients
NCT02356679
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MCT-SR
Drug: MCT-SR 2 times/day for 2 weeks
MCT-SR
Rebamipide 150mg
Mucosta Tab.
Rebamipide 100mg
Mucosta Tab.
Drug: Mucosta Tab. 3 times/day for 2 weeks
MCT-SR
Rebamipide 150mg
Mucosta Tab.
Rebamipide 100mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MCT-SR
Rebamipide 150mg
Mucosta Tab.
Rebamipide 100mg
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients diagnosed with acute or chronic gastritis by gastroscopy with at least 1 erosion confirmed by gastroscopy within 7 days prior to the first dose of the Investigational Product(IP)
Exclusion Criteria
* Patients who took other drugs for treating gastritis within 2 weeks prior to the first dose of the IP.
* Patients who have to continue taking drugs that may induce gastritis
* Other clinically significant medical or psychiatric findings that the investigator considers inappropriate for the study
19 Years
74 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Korea Otsuka Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
JaeGyu Kim, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Chung-Ang University Hosptial, Chung-Ang University College of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chung-Ang University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
037-402-00039
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.